Founder, DEKA Research and Development Corporation
Chairman and CEO, Nanobiosym Diagnostics Inc.
Founder and CEO, Acme Packet
CTO, BuddyTV
Professor of Bioengineering, University of Washington
Director, Energy Biosciences Inst., UC Berkeley
Partner, Third Rock Ventures
President and CEO, Allozyne
|
Pro-Pharmaceuticals of Newton, MA, announced today that it got the go-ahead from the FDA to treat one breast cancer patient with its lead drug candidate, Davanat. The drug, a carbohydrate polymer currently in Phase II trials for colorectal and biliary cancers, is designed to be used in combination with other cancer treatments.
San Francisco · 6/7/12
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
